Related Experiment Videos
No evidence of a role for activating CDK2 mutations in melanoma
1Queensland Cancer Fund Research Unit, Joint Experimental Oncology Program, Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, QLD 4029, Australia. graemeW@qimr.edu.au
Abstract:
Inactivation of p16INK4a and/or activation of cyclin-dependent kinase-4 (CDK4) are strongly associated with both susceptibility and progression in melanoma. Activating CDK4 mutations prevent the binding and inhibition of CDK4 by p16INK4a. A second, more indirect role for CDK4 is in late G1, where it may sequester the inhibitors p27KIP1 or p21CIP1 away from CDK2, and in doing so upregulate the CDK2 activity necessary for cells to proceed completely through G1 into S phase. As the pivotal residues around the most predominant R24C activating CDK4 mutation are invariant between CDK2 and CDK4, we speculated that the pivotal arginine (position 22 in CDK2), or a nearby residue, may be mutated in some melanomas, resulting in the diminution of its binding and inhibition by p27KIP1 or p21CIP1. However, except for a silent polymorphism, we detected no variants within this region of the CDK2 gene in 60 melanoma cell lines. Thus, if CDK2 activity is dysregulated in melanoma it is likely to occur by a means other than mutations causing loss of direct inhibition. We also examined the expression of the CDK2 gene in melanoma cell lines, to assess its possible co-regulation with the gene for the melanocyte-lineage antigen pmel17, which maps less than 1 kb away in head to head orientation with CDK2 and may be transcribed off the same bidirectional promoter. However, expression of the genes is not co-regulated.
Insights
Melanoma progression involves cyclin-dependent kinase-4 (CDK4) and p16INK4a. Researchers found no CDK2 gene mutations in melanoma cell lines, suggesting other mechanisms regulate CDK2 activity in this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cyclin-dependent kinase-4 (CDK4) dysregulation and p16INK4a inactivation are linked to melanoma susceptibility and progression.
- CDK4 mutations can impede p16INK4a inhibition, while CDK4 may indirectly affect CDK2 activity by sequestering inhibitors like p27KIP1 or p21CIP1.
Purpose of the Study:
- To investigate potential mutations in the CDK2 gene, specifically in residues critical for p27KIP1 or p21CIP1 binding, as a mechanism for CDK2 dysregulation in melanoma.
- To examine the co-regulation of CDK2 gene expression with the pmel17 gene in melanoma cell lines.
Main Methods:
- Sequencing of the CDK2 gene in 60 melanoma cell lines to identify variants in key regulatory regions.
- Analysis of CDK2 gene expression in melanoma cell lines.
- Assessment of potential co-regulation between CDK2 and pmel17 genes, which are located proximally and may share a bidirectional promoter.
Main Results:
- No significant mutations, apart from a silent polymorphism, were found in the investigated region of the CDK2 gene across 60 melanoma cell lines.
- CDK2 gene expression was not found to be co-regulated with the pmel17 gene in melanoma cell lines.
Conclusions:
- Direct mutations leading to loss of p27KIP1 or p21CIP1 inhibition of CDK2 are unlikely to be a common mechanism in melanoma.
- CDK2 activity dysregulation in melanoma likely occurs through alternative pathways not involving direct mutations in the screened region.
- The CDK2 and pmel17 genes are not co-regulated in melanoma cell lines, despite their close genomic proximity.